Cardinal Health, an Ohio-based health care services company has signed a deal to divest its drug distribution business in China to Shanghai Pharmaceuticals (Shanghai Pharma) for $557m.
Torrent Pharmaceuticals has entered into a definitive binding agreement with Unichem to acquire its branded business of India and Nepal (India business) for a consideration of Rs3600 crores.
Novartis has agreed to acquire French radiopharmaceutical company Advanced Accelerator Applications (AAA) for $3.9bn to strengthen its oncology presence.
Clinigen Group has acquired International Medical Management (IMMC), Japan’s largest supplier of unlicensed medicines, for an undisclosed sum.
Amneal Pharmaceuticals has agreed to buy Impax Laboratories in an all-stock deal to create a diversified pharmaceutical firm that is expected to become the fifth largest generics business in the US.
Catalent has agreed to acquire Indiana-based contract development and manufacturing organization (CDMO) Cook Pharmica for $950m to consolidate its position in the bio-pharma sector.
Bioverativ and Bicycle Therapeutics have announced a research collaboration focused on the discovery, development and commercialization of innovative therapies for hemophilia and sickle cell disease.
Aptevo Therapeutics has agreed to sell its three marketed hyperimmune products, WinRho SDF, HepaGam B, and VARIZIG, to Saol Therapeutics for total consideration of up to $74.5m.
AstraZeneca and Takeda Pharmaceutical have entered into an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).
Forma Therapeutics and Celgene announced an innovative R&D partnership in 2014 to pursue ground-breaking medicines in oncology and other therapeutic areas.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.